Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
The Lancet5h
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...
pulmonologyadvisor1d
Cystic Fibrosis: GI Symptom Relief From ETI Wanes Over Long Term
In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.
thorax.bmj4d
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
pharmaphorum2d
Share in cystic fibrosis firm Sionna rise sharply after IPO
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
FiercePharma1d
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Armed robbery in Revesby9d
Enid's Cystic Fibrosis Clinical Trial Offers Hope
By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...
BlackDoctor15d
When Cystic Fibrosis Hits the Lungs, HIT BACK
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is right ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...